TCIM
NKTR icon

TIAA CREF Investment Management’s Nektar Therapeutics NKTR Stock Holding History

TIAA CREF Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$19.4M Buy
38,558
+12,605
+49% +$7.47M 0.01% 719
2018
Q4 		$12.8M Sell
25,953
-2,703
-9% -$1.63M 0.01% 836
2018
Q3 		$26.2M Buy
28,656
+869
+3% +$742K 0.02% 631
2018
Q2 		$20.4M Sell
27,787
-15,173
-35% -$17.5M 0.01% 738
2018
Q1 		$68.5M Buy
42,960
+1,260
+3% +$1.62M 0.05% 367
2017
Q4 		$37.4M Buy
41,700
+4,767
+13% +$2.82M 0.02% 534
2017
Q3 		$13.3M Sell
36,933
-1,408
-4% -$440K 0.01% 978
2017
Q2 		$11.2M Sell
38,341
-10,667
-22% -$3.08M 0.01% 1061
2017
Q1 		$17.3M Buy
49,008
+8,984
+22% +$2.02M 0.01% 814
2016
Q4 		$7.37M Buy
40,024
+2,557
+7% +$520K 0.01% 1329
2016
Q3 		$9.65K Sell
37,467
-592
-2% -$152K 0.01% 1141
2016
Q2 		$8.12M Sell
38,059
-1,396
-4% -$312K 0.01% 1193
2016
Q1 		$8.14M Sell
39,455
-601
-2% -$115K 0.01% 1176
2015
Q4 		$10.1M Sell
40,056
-621
-2% -$128K 0.01% 1062
2015
Q3 		$6.69M Sell
40,677
-1,392
-3% -$246K 0.01% 1334
2015
Q2 		$7.89M Sell
42,069
-6,206
-13% -$1.07M 0.01% 1331
2015
Q1 		$7.96M Sell
48,275
-309
-0.6% -$63.5K 0.01% 1304
2014
Q4 		$11.3M Sell
48,584
-1,634
-3% -$349K 0.01% 1037
2014
Q3 		$9.09M Sell
50,218
-885
-2% -$169K 0.01% 1155
2014
Q2 		$9.83M Buy
51,103
+1,575
+3% +$279K 0.01% 1173
2014
Q1 		$9M Buy
49,528
+997
+2% +$197K 0.01% 1205
2013
Q4 		$8.26M Sell
48,531
-229
-0.5% -$36.9K 0.01% 1275
2013
Q3 		$7.64M Sell
48,760
-651
-1% -$120K 0.01% 1265
2013
Q2 		$8.56M Buy
+49,411
New +$7.58M 0.01% 1145

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TIAA CREF Investment Management's NKTR Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Nektar Therapeutics (NKTR) stake by 49% in Q1 2019, buying an estimated $7.47M and bringing the position to 38,558 shares worth $19.4M. The position accounts for 0.01% of the portfolio, ranked #719.

TIAA CREF Investment Management first reported a position in NKTR in Q2 2013 and has held it in 24 quarters since. The position peaked at $68.5M in Q1 2018. 349 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • TIAA CREF Investment Management held 38,558 shares of Nektar Therapeutics worth $19.4M as of Q1 2019.
  • TIAA CREF Investment Management bought 12,605 Nektar Therapeutics shares in Q1 2019, an estimated $7.47M.
  • Nektar Therapeutics made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #719 holding.
  • TIAA CREF Investment Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Nektar Therapeutics position peaked at $68.5M in Q1 2018.
  • 349 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.